EuBiologics Co., Ltd. (206650.KQ)

KRW 12130.0

(-3.58%)

Market Cap (In KRW)

443.16 Billion

Revenue (In KRW)

69.36 Billion

Net Income (In KRW)

-13.87 Billion

Avg. Volume

205.48 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
9350.0-18800.0
PE
-
EPS
-
Beta Value
1.249
ISIN
KR7206650004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Yeong-Ok Baik
Employee Count
-
Website
http://www.eubiologics.com
Ipo Date
2017-01-24
Details
EuBiologics Co., Ltd., a biopharmaceutical company, develops and supplies vaccines for epidemics and antibiotic resistance in South Korea. It offers Euvchol, an oral cholera prevention vaccine; and CRM197, a diphtheria toxin mutant vaccine. The company also provides customized services for mammalian cell and microbial cell derived biopharmaceuticals in accordance with the clients' project stages, including cell line development, GMP production, validation, and the regulatory support; and operates facilities that manufacture protein-based therapeutics and antibodies. It specializes in manufacturing a range of mammalian cell and microbial cell derived biopharmaceuticals, including recombinant biological products and antibody therapeutics. In addition, the company offers process, formulation, and analytical method development, as well as licensing consulting services; and contract testing services that include lot release, stability, raw material, and method validation testing services. The company was founded in 2010 and is based in Seoul, South Korea.